# Efficacy of 12 Weeks Versus 24 Weeks Treatment of Directly Acting Antiviral Therapy in Patients With Hepatitis C Related Chronic Liver Disease

> **NCT07702396** · NA · COMPLETED · sponsor: **Indus Hospital and Health Network** · enrollment: 192 (actual)

## Conditions studied

- Heptatitis C

## Interventions

- **OTHER:** 12 weeks Sofosbuvir 400 mg once daily, Daclatasvir 60 mg once daily, and Ribavirin 400 mg twice daily

## Key facts

- **NCT ID:** NCT07702396
- **Lead sponsor:** Indus Hospital and Health Network
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-10
- **Primary completion:** 2024-09-20
- **Final completion:** 2024-09-20
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2026-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07702396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07702396, "Efficacy of 12 Weeks Versus 24 Weeks Treatment of Directly Acting Antiviral Therapy in Patients With Hepatitis C Related Chronic Liver Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07702396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*